Canada · Delayed Price · Currency is CAD Cipher Pharmaceuticals Company Description
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults.
Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage.
The company was founded in 2000 and is headquartered in Mississauga, Canada.
| Country | Canada |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Craig Mull |
Contact Details
Address: 5750 Explorer Drive Mississauga, Ontario L4W 0A9 Canada | |
| Phone | 905 602 5840 |
| Website | cipherpharma.com |
Stock Details
| Ticker Symbol | CPH |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA17253X1050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig J. Mull | Interim Chief Executive Officer and Chairman of the Board |
| Bryan Jacobs | President |
| Ryan Mailling | Chief Financial Officer |
| Emilio Presti | Director of Sales and Marketing |
| Shengnan Guo | Corporate Controller |